Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
about
Human immunodeficiency virus & cardiovascular riskNarrative review: the role of leptin in human physiology: emerging clinical applicationsTiming of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studiesChanges in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDSHigh frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virusAssociations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.Antiretroviral therapy and dyslipidaemia: unlocking the code.Drug Induced Steatohepatitis: An Uncommon Culprit of a Common DiseaseMetabolic syndrome, diabetes, and cardiovascular risk in HIVLeptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individualsMenopause-associated metabolic manifestations and symptomatology in HIV infection: a brief review with research implicationsAssociation of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysisMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsThe other genome: a systematic review of studies of mitochondrial DNA haplogroups and outcomes of HIV infection and antiretroviral therapyA review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalizationAtazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic ReviewManaging dyslipidemia in HIV/AIDS patients: challenges and solutionsHIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsSystematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reactionThe burden of image based emphysema and bronchiolitis in HIV-infected individuals on antiretroviral therapyHIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitusPredictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudineHypertriglyceridemia and waist circumference predict cardiovascular risk among HIV patients: a cross-sectional studyAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring.Ultrasound-assessed perirenal fat is related to increased ophthalmic artery resistance index in HIV-1 patients.Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus.Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts.Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.Does HIV cause cardiovascular disease?Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.Creatine fails to augment the benefits from resistance training in patients with HIV infection: a randomized, double-blind, placebo-controlled study.Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).Leptin revisited: its mechanism of action and potential for treating diabetes.Smoking cessation among women with and at risk for HIV: are they quitting?The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.Coagulation and morbidity in treated HIV infection.Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavirScreening for chronic kidney disease in HIV-infected patients.
P2860
Q22241184-49DB6000-D75B-49D7-89A4-294F247B446DQ24634811-75D15C85-EA34-425E-B485-A0A9FE2F1FB2Q24656950-F1646117-E363-4F92-A38D-D512AD457657Q24792952-9BCD0F4B-D3C7-4578-9A8E-0C8668D0A105Q24814179-B3EC3548-7D63-4CA7-B207-D080AABF14B8Q25255216-2D40659C-FABE-485B-9933-C2A24614AFCBQ25256933-0796E49A-9073-436A-B268-31B6ABC7004DQ26798157-FFECC16B-D095-4BEF-B5B1-432DD3F5AA58Q26853470-CC83C672-310B-49C7-83C0-C40562A08C62Q26859118-BCA04098-5F89-4828-A6DC-9438DFA75FDEQ26865187-71E9F0BB-3623-49FE-84D6-0ED03FFC0A3FQ27000959-8943B7D3-1651-43DF-B3A9-C0DAAA896567Q27024262-74D84CB7-485E-4901-8759-E84E19AF9705Q27027887-C5780574-2CF2-44BF-A76E-DAF89ED156D3Q27498795-38748701-1FCF-4565-B4A6-6D8E8C7D5B04Q28080289-E165A284-84B8-488D-95FC-F63CEFA31FC5Q28084941-2867E927-2181-49A6-899D-FEAA3169F66AQ28088839-BF68F10E-611B-4E3E-897C-CAB9664BF3AFQ28533379-23DFC0B4-3728-42CF-B3B7-1AF41443A2CBQ28544453-5D32547F-0791-42AE-BC34-5621DC548A4DQ28582686-02446B26-BF51-45F8-ABD8-08656516142BQ28743352-51664D84-7B33-4772-A652-7748E21972A9Q28744647-73122A5F-9D5E-4CC1-9E4A-99996B2004AFQ30248286-342992BF-1862-4777-BBC4-2D6501835DE2Q30249830-97D7D0C8-28F1-40A1-9FB0-B96BA8D7C27AQ30480466-92AF90E3-DD27-4E91-9882-C41F20F900E5Q30576375-C3ADD29F-29B6-41D7-8C3A-2BD98B9CD74CQ30978868-BD5A1284-F775-49CB-84C3-8B12F4C45F72Q31143771-D8C7C76E-4697-4EB5-BDCE-49A4E89D8AF7Q33264851-2644C756-F423-4178-B7D0-739E074CAC59Q33330313-85F21709-7975-44A0-8B7E-B47669C829F9Q33412387-8653CC97-B887-478C-8AB2-495161760182Q33455840-DD7033EE-2E9B-44C7-9A8B-5379F249B231Q33600363-1193783E-33EB-4FAB-B19E-417BA1F4D749Q33602487-8B84BBFE-984E-4746-9424-D69DB4DBE350Q33611409-DBE31952-28A4-4D5E-A65E-B8DC0BE6EF6DQ33614139-FE9DDE81-3152-46F6-89AB-13C9DBA3884CQ33614424-ADA89D5D-0254-4EF7-A9C7-FAF42B1E072BQ33625135-386BBA92-0C49-42EF-BED9-397D371404F7Q33639802-44E78F35-28D3-4162-BB4B-9B22C5ED573D
P2860
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
@ast
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
@en
type
label
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
@ast
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
@en
prefLabel
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
@ast
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
@en
P356
P1476
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
@en
P2093
Andrew Carr
Steven Grinspoon
P356
10.1056/NEJMRA041811
P407
P577
2005-01-01T00:00:00Z